PureTech Health PLC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert William Henry Lyne
- Full Time Employees
- 56
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 6 Tide Street Boston MA United States 02210
- IPO Date
- Jun 24, 2015
- Website
- puretechhealth.com
- Similar Companies
- Business
- PureTech Health plc is a clinical-stage biopharmaceutical company focused on discovering and developing new classes of medicines to address devastating diseases. Founded in 2015 and headquartered in London, United Kingdom, the company operates through a capital-efficient hub-and-spoke R&D model that advances therapeutic candidates internally and through a portfolio of Founded Entities supported by external capital. PureTech's product pipeline includes approximately 29 therapeutics and therapeutic candidates across various disease areas, with core products including deupirfenidone (LYT-100), a Phase 3-ready drug candidate aimed at treating idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, and LYT-200, an anti-galectin-9 monoclonal antibody targeting hematological malignancies such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors like metastatic head and neck cancer. Recent developments include the launch of Celea Therapeutics in 2025 to advance deupirfenidone for lung fibrosis indications, marking an important strategic expansion focused on respiratory diseases. The company also launched Seaport Therapeutics, securing $100 million in funding to advance neuropsychiatric drug candidates, including a novel prodrug for generalized anxiety disorder. PureTech continues to progress LYT-200 through its Founded Entity Gallop Oncology, which has received FDA Fast Track and Orphan Drug designations for AML and demonstrated promising clinical activity in early trials. A notable milestone in 2024 was the FDA approval of Cobenfy (formerly KarXT), an antipsychotic treatment for schizophrenia developed by Karuna Therapeutics, a PureTech Founded Entity, which was acquired by Bristol Myers Squibb for approximately $14 billion. PureTech operates globally with a significant focus on the United States for clinical development and commercialization. Its strategy emphasizes identifying and de-risking high-potential assets, advancing them through strategic partnerships, equity holdings, milestone payments, and royalties while maintaining a strong financial position, including over $300 million in cash and equivalents as of mid-2025. The company targets markets including rare diseases, oncology, neuropsychiatric disorders, and pulmonary fibrosis, leveraging its innovative biotech platform and diversified portfolio to generate value for patients and shareholders. PureTech Health plc’s approach combines cutting-edge science with capital discipline, positioning it as a leading player in biotechnology innovation dedicated to transforming healthcare through novel therapeutics.
Company News
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
PureTech Health gets Panmure Liberum ‘buy' on value and cash returns
PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript
PureTech Health H1 Earnings Call Highlights
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplast
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
PureTech Health: Notice of Half-Yearly Results
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech Health: Results of Annual General Meeting
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
Short Interest in PureTech Health plc (OTCMKTS:PTCHF) Expands By 69.4%